At a glance
- Originator POLYPID
- Class Anthracyclines; Antineoplastics; Cytostatic antibiotics; Doxorubicins; Small molecules
- Mechanism of Action DNA intercalators; Type II DNA topoisomerase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
- Available For Licensing Yes - Cancer
Highest Development Phases
- No development reported Cancer
Most Recent Events
- 28 Apr 2021 No recent reports of development identified for preclinical development in Cancer in Israel (Controlled release)
- 21 Apr 2017 Chemical structure information added
- 29 Mar 2017 Doxorubicin - POLYPID is available for licensing as of 29 Mar 2017. http://www.polypid.com